CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 5,500 target
Drug / intervention
Camizestrant +5 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Women and Men aged ≥18 years
  • ✓Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with no metastatic disease
  • ✓Completed adequate locoregional therapy (surgery ± radiotherapy) ± (neo)adjuvant chemotherapy
  • ✓Randomized within 12 months of definitive breast surgery
Key exclusion· 11
  • ✕Inoperable locally advanced or metastatic breast cancer
  • ✕Pathological complete response following neoadjuvant therapy
  • ✕History of other cancer unless in complete remission for minimum 5 years (excludes non-melanoma skin cancer or cervical carcinoma in situ)
  • ✕Severe or uncontrolled systemic disease precluding participation or compliance

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

5 articles

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT05952557
NCT05952557Phase 3RecruitingHigh Momentum
CompareCT.gov

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

AstraZeneca·interventional·Posted Jul 19, 2023·Updated Jun 25, 2026

In Brief

A Phase 3 clinical trial evaluating Camizestrant, Tamoxifen, and 4 other interventions for Breast Cancer, Early Breast Cancer. Currently recruiting, targeting 5,500 participants across 798 sites in 44 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Early Breast Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Serbia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom, United States
CollaboratorsAustrian Breast & Colorectal Cancer Study Group

Timeline

Phase 3Recruiting
20242025202620272028202920302031203220332034203520362037
First PostedJul 19, 2023
Enrollment StartOct 5, 2023
Primary CompletionMar 4, 2030
Study CompletionMay 6, 2037
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 3.0 years agoPrimary completion in 3.7 years

Arms & Interventions

Arm A: standard endocrine therapy of investigator´s choice ± abemaciclibactive_comparator

standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) ± abemaciclib

Drug: TamoxifenDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: Abemaciclib
Arm B: camizestrant ± abemaciclibexperimental

camizestrant ± abemaciclib

Drug: CamizestrantDrug: Abemaciclib

Interventions

Camizestrantdrug

Camizestrant. Experimental. Administered orally

Tamoxifendrug

Tamoxifen. Comparator. Administered orally

Anastrozoledrug

Anastrozole. Comparator. Administered orally

Letrozoledrug

Letrozole. Comparator. Administered orally

Exemestanedrug

Exemestane. Comparator. Administered orally

Abemaciclibdrug

Abemaciclib adjuvant treatment Administered orally